ARMD9
MCID: MCL044
MIFTS: 23

Macular Degeneration, Age-Related, 9 (ARMD9) malady

Categories: Genetic diseases, Eye diseases, Rare diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Macular Degeneration, Age-Related, 9

Aliases & Descriptions for Macular Degeneration, Age-Related, 9:

Name: Macular Degeneration, Age-Related, 9 54 66 13 69
Armd9 12 24 66
Age-Related Macular Degeneration 9 24 29
Age Related Macular Degeneration 9 12

Classifications:



External Ids:

OMIM 54 611378
Disease Ontology 12 DOID:0110021
MedGen 40 C1969651
MeSH 42 D008268

Summaries for Macular Degeneration, Age-Related, 9

UniProtKB/Swiss-Prot : 66 Macular degeneration, age-related, 9: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

MalaCards based summary : Macular Degeneration, Age-Related, 9, also known as armd9, is related to macular degeneration, age-related, 1. An important gene associated with Macular Degeneration, Age-Related, 9 is C3 (Complement C3). The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye.

Disease Ontology : 12 An age related macular degeneration conferred by variation in the C3 gene on chromosome 19p13.

Description from OMIM: 611378

Related Diseases for Macular Degeneration, Age-Related, 9

Symptoms & Phenotypes for Macular Degeneration, Age-Related, 9

Clinical features from OMIM:

611378

Drugs & Therapeutics for Macular Degeneration, Age-Related, 9

Drugs for Macular Degeneration, Age-Related, 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
2
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
4
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
5
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
6 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
7 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
8 Betamethasone Valerate Phase 4 2152-44-5
9 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
10 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
11
protease inhibitors Phase 4,Phase 3,Phase 2
12 Mitogens Phase 4,Phase 2,Phase 3
13 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
14 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
15 Norgestimate, ethinyl estradiol drug combination Phase 4
16 Topoisomerase Inhibitors Phase 4
17 Homatropine Phase 4
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
19 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2
20 Hormones Phase 4,Phase 3,Phase 2,Phase 1
21 Parasympatholytics Phase 4
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Endothelial Growth Factors Phase 4,Phase 2,Phase 3
25 Anti-Asthmatic Agents Phase 4
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
27 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Antiemetics Phase 4,Phase 3,Phase 2
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Respiratory System Agents Phase 4
31 Antibiotics, Antitubercular Phase 4,Phase 2
32 BB 1101 Phase 4,Phase 3,Phase 2
33 Autonomic Agents Phase 4,Phase 3,Phase 2
34 Betamethasone benzoate Phase 4
35 Betamethasone sodium phosphate Phase 4
36 Betamethasone-17,21-dipropionate Phase 4
37 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
38
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
39
Verteporfin Approved, Investigational Phase 3,Phase 1,Phase 2 129497-78-5
40
Triamcinolone Approved, Vet_approved Phase 3,Phase 1 124-94-7 31307
41 triamcinolone acetonide Phase 3,Phase 1
42
Ruboxistaurin Phase 3 202260-21-7 153999
43 Cortisol succinate Phase 3
44 Dermatologic Agents Phase 3,Phase 1,Phase 2
45 Ophthalmic Solutions Phase 3,Phase 1
46 Anecortave Phase 3
47 Triamcinolone diacetate Phase 3,Phase 1
48 Triamcinolone hexacetonide Phase 3,Phase 1
49 Hydrocortisone 17-butyrate 21-propionate Phase 3
50 Hydrocortisone acetate Phase 3

Interventional clinical trials:

(show top 50) (show all 69)
id Name Status NCT ID Phase
1 PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization Completed NCT00358345 Phase 4
2 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4
3 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Recruiting NCT02471651 Phase 4
4 TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration Unknown status NCT00260403 Phase 2, Phase 3
5 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME) Unknown status NCT01635790 Phase 2, Phase 3
6 Systemic Avastin Therapy in Age-Related Macular Degeneration Completed NCT00531024 Phase 2, Phase 3
7 Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD) Completed NCT00299507 Phase 3
8 A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Completed NCT00242580 Phase 3
9 A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) Completed NCT00891735 Phase 3
10 Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) Completed NCT01135914 Phase 3
11 Effect of Ruboxistaurin on Clinically Significant Macular Edema Completed NCT00133952 Phase 3
12 Reduction in the Occurrence of Center-Involved Diabetic Macular Edema Completed NCT00090519 Phase 3
13 Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients Recruiting NCT02296567 Phase 2, Phase 3
14 A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Patients With Diabetic Macular Edema Recruiting NCT02121262 Phase 3
15 Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD Active, not recruiting NCT02727881 Phase 3
16 Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis Suspended NCT00460967 Phase 3
17 Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase Terminated NCT02032173 Phase 3
18 Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System Unknown status NCT00100087 Phase 1, Phase 2
19 Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab Unknown status NCT01845844 Phase 1, Phase 2
20 Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT01162746 Phase 2
21 Lutein for Age-Related Macular Degeneration Completed NCT00006202 Phase 2
22 Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) Completed NCT00935883 Phase 2
23 Photodynamic and Pharmacologic Treatment of CNV Completed NCT00570193 Phase 1, Phase 2
24 Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab Completed NCT00804921 Phase 2
25 Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00284089 Phase 1, Phase 2
26 Lucentis for Inflammatory Macular Edema Trial Completed NCT00498355 Phase 1, Phase 2
27 Effect of Choline Fenofibrate (SLV348) on Macular Edema Completed NCT00683176 Phase 2
28 Ranibizumab and Bevacizumab for Diabetic Macular Edema Completed NCT01610557 Phase 2
29 Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab Completed NCT01292798 Phase 1, Phase 2
30 Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa Completed NCT02140164 Phase 1, Phase 2
31 A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Completed NCT00336323 Phase 2
32 Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration Recruiting NCT02286089 Phase 1, Phase 2
33 Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema Recruiting NCT02732951 Phase 2
34 Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) Active, not recruiting NCT01552408 Phase 1, Phase 2
35 Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy Terminated NCT01675947 Phase 2
36 Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration Terminated NCT01577381 Phase 2
37 Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD) Completed NCT01301443 Phase 1
38 Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy Completed NCT00060749 Phase 1
39 Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60 Completed NCT00121589 Phase 1
40 Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders Completed NCT00071227 Phase 1
41 Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD Completed NCT02022540 Phase 1
42 Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X Completed NCT01869933 Phase 1
43 Vitamin E to Treat Uveitis-Associated Macular Edema Completed NCT00021645 Phase 1
44 Laser and Medical Treatment of Diabetic Macular Edema Completed NCT00027287 Phase 1
45 Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema Completed NCT00403039 Phase 1
46 RGX-314 Gene Therapy for Neovascular AMD Trial Recruiting NCT03066258 Phase 1
47 Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Active, not recruiting NCT01024998 Phase 1
48 Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348672
49 Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348633
50 A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. Completed NCT00549055

Search NIH Clinical Center for Macular Degeneration, Age-Related, 9

Genetic Tests for Macular Degeneration, Age-Related, 9

Genetic tests related to Macular Degeneration, Age-Related, 9:

id Genetic test Affiliating Genes
1 Age-Related Macular Degeneration 9 29 24 C3

Anatomical Context for Macular Degeneration, Age-Related, 9

MalaCards organs/tissues related to Macular Degeneration, Age-Related, 9:

39
Eye

Publications for Macular Degeneration, Age-Related, 9

Variations for Macular Degeneration, Age-Related, 9

UniProtKB/Swiss-Prot genetic disease variations for Macular Degeneration, Age-Related, 9:

66
id Symbol AA change Variation ID SNP ID
1 C3 p.Lys155Gln VAR_070941 rs147859257

Expression for Macular Degeneration, Age-Related, 9

Search GEO for disease gene expression data for Macular Degeneration, Age-Related, 9.

Pathways for Macular Degeneration, Age-Related, 9

GO Terms for Macular Degeneration, Age-Related, 9

Sources for Macular Degeneration, Age-Related, 9

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....